Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.55 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | SNCA | P37840 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.38 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.37 |
| ▸ | CDC25B | P30305 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7944875 | 1.00 | BLM (0.57) | BLMLMNAPTPN1KDM1AMEN1 | |
| SCHEMBL15825692 | 1.00 | BLM (0.57) | BLMLMNAPTPN1KDM1AMEN1 | |
| SCHEMBL6822195 | 1.00 | BLM (0.57) | BLMLMNAPTPN1KDM1AMEN1 | |
| SCHEMBL7943009 | 1.00 | BLM (0.57) | BLMLMNAPTPN1KDM1AMEN1 | |
| SCHEMBL15824542 | 1.00 | BLM (0.57) | BLMLMNAPTPN1KDM1AMEN1 | |
| SCHEMBL8908184 | 1.00 | BLM (0.57) | BLMLMNAPTPN1KDM1AMEN1 | |
| SCHEMBL716506 | 1.00 | BLM (0.57) | BLMLMNAPTPN1KDM1AMEN1 | |
| SCHEMBL7942967 | 1.00 | BLM (0.57) | BLMLMNAPTPN1KDM1AMEN1 | |
| SCHEMBL117939 | 1.00 | BLM (0.57) | BLMLMNAPTPN1KDM1AMEN1 | |
| SCHEMBL6822085 | 1.00 | BLM (0.57) | BLMLMNAPTPN1KDM1AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2935177-B1 | (6R,10R)-6,10,14-TRIMETYLPENTADECAN-2-ONE PREPARED FROM 6,10-DIMETYLUNDEC-5-EN-2-ONE OR 6,10-DIMETYLUNDECA-5,9-DIEN-2-ONE | DSM IP ASSETS BV (NL) | 2019-07-24 | — | — | EP | disclosed |
| EP-2935189-B1 | USING MIXTURES OF E/Z ISOMERS TO OBTAIN QUANTITATIVELY SPECIFIC PRODUCTS BY COMBINING ASYMMETRIC HYDROGENATION AND ISOMERIZATION | DSM IP ASSETS BV (NL) | 2019-06-12 | — | — | EP | disclosed |
| EP-2935175-B1 | (6R,10R)-6,10,14-TRIMETYLPENTADECAN-2-ONE PREPARED FROM (R)-6,10,14-TRIMETYLPENTADEC-5-EN-2-ONE | DSM IP ASSETS BV (NL) | 2018-09-19 | — | — | EP | disclosed |
| EP-2935191-B1 | PREPARATION OF (6R,10R)-6,10,14-TRIMETYLPENTADECAN-2-ONE FROM 3,7-DIMETYLOCT-2-ENAL OR 3,7-DIMETYLOCTA-2,6-DIENAL | DSM IP ASSETS BV (NL) | 2018-08-01 | — | — | EP | disclosed |
| EP-2935176-B1 | (6R,10R)-6,10,14-TRIMETYLPENTADECAN-2-ONE PREPARED FROM (R)-3,7-DIMETYLOCT-6-ENAL | DSM IP ASSETS BV (NL) | 2018-08-01 | — | — | EP | disclosed |
| US-9573872-B2 | Using mixtures of E/Z isomers to obtain quantitatively specific products by combining asymmetric hydrogenation and isomerization | DSM IP ASSETS B.V. (NL) | 2017-02-21 | — | — | US | disclosed |
| EP-2720996-B1 | HYDROGENATION OF KETONES HAVING AT LEAST A CARBON-CARBON DOUBLE BOND IN THE gamma,delta-POSITION | DSM IP ASSETS BV (NL) | 2016-10-12 | — | — | EP | disclosed |
| US-9458076-B2 | Using mixtures of E/Z isomers to obtain quantitatively specific products by combined asymmetric hydrogenations | DSM IP ASSETS B.V. (NL) | 2016-10-04 | — | — | US | disclosed |
| US-20160185702-A1 | USING MIXTURES OF E/Z ISOMERS TO OBTAIN QUANTITATIVELY SPECIFIC PRODUCTS BY COMBINING ASYMMETRIC HYDROGENATION AND ISOMERIZATION | DSM IP ASSETS B.V. (NL) | 2016-06-30 | — | — | US | disclosed |
| US-20150321986-A1 | USING MIXTURES OF E/Z ISOMERS TO OBTAIN QUANTITATIVELY SPECIFIC PRODUCTS BY COMBINED ASYMMETRIC HYDROGENATIONS | DSM IP ASSETS B.V. (NL) | 2015-11-12 | — | — | US | disclosed |
| US-9181163-B2 | Hydrogenation of ketones having at least a carbon-carbon double bond in the γ,δ-position | DSM IP ASSETS B.V. (NL) | 2015-11-10 | — | — | US | disclosed |
| EP-2935188-A1 | USING MIXTURES OF E/Z ISOMERS TO OBTAIN QUANTITATIVELY SPECIFIC PRODUCTS BY COMBINED ASYMMETRIC HYDROGENATIONS | DSM IP Assets B.V. (NL) | 2015-10-28 | — | — | EP | disclosed |
| EP-2935191-A1 | (6R,10R)-6,10,14-TRIMETYLPENTADECAN-2-ONE PREPARED FROM 3,7-DIMETYLOCT-2-ENAL OR 3,7-DIMETYLOCTA-2,6-DIENAL | DSM IP Assets B.V. (NL) | 2015-10-28 | — | — | EP | disclosed |
| EP-2935175-A1 | (6R,10R)-6,10,14-TRIMETYLPENTADECAN-2-ONE PREPARED FROM (R)-6,10,14-TRIMETYLPENTADEC-5-EN-2-ONE | DSM IP Assets B.V. (NL) | 2015-10-28 | — | — | EP | disclosed |
| US-20140249321-A1 | HYDROGENATION OF KETONES HAVING AT LEAST A CARBON-CARBON DOUBLE BOND IN THE y, -POSITION | DSM IP ASSETS B.V. (NL) | 2014-09-04 | — | — | US | disclosed |
| WO-2014096067-A1 | (6R,10R)-6,10,14-TRIMETYLPENTADECAN-2-ONE PREPARED FROM (R)-6,10,14-TRIMETYLPENTADEC-5-EN-2-ONE | DSM IP ASSETS B.V. (NL) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014096106-A1 | USING MIXTURES OF E/Z ISOMERS TO OBTAIN QUANTITATIVELY SPECIFIC PRODUCTS BY COMBINED ASYMMETRIC HYDROGENATIONS | DSM IP ASSETS B.V. (NL) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014096063-A1 | (6R,10R)-6,10,14-TRIMETYLPENTADECAN-2-ONE PREPARED FROM 3,7-DIMETYLOCT-2-ENAL OR 3,7-DIMETYLOCTA-2,6-DIENAL | DSM IP ASSETS B.V. (NL) | 2014-06-26 | — | — | WO | disclosed |
| EP-2720996-A1 | HYDROGENATION OF KETONES HAVING AT LEAST A CARBON-CARBON DOUBLE BOND IN THE , -POSITION | DSM IP Assets B.V. (NL) | 2014-04-23 | — | — | EP | disclosed |
| WO-2012171969-A1 | HYDROGENATION OF KETONES HAVING AT LEAST A CARBON-CARBON DOUBLE BOND IN THE γ, δ-POSITION | DSM IP ASSETS B.V. (NL) | 2012-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249321-A1 | HYDROGENATION OF KETONES HAVING AT LEAST A CARBON-CARBON DOUBLE BOND IN THE y, -POSITION | VKORC1, VKORC1L1, CBR1 | BLM 4811/4885LMNA 2929/4885PTPN1 4877/4885 |
| US-20150321986-A1 | USING MIXTURES OF E/Z ISOMERS TO OBTAIN QUANTITATIVELY SPECIFIC PRODUCTS BY COMBINED ASYMMETRIC HYDROGENATIONS | EPHX2, HBZ, ELOVL5 | BLM 3567/4885LMNA 681/4885PTPN1 4872/4885 |
| US-20160185702-A1 | USING MIXTURES OF E/Z ISOMERS TO OBTAIN QUANTITATIVELY SPECIFIC PRODUCTS BY COMBINING ASYMMETRIC HYDROGENATION AND ISOMERIZATION | EPHX2, ZDHHC2, GNE | BLM 3664/4885LMNA 977/4885PTPN1 4862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.